Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 10/20 | 0.65 |
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25252763 | 0.84 | MAPT (0.51) | TP53MAPTKDM4EHSD17B10NPC1 | |
| SCHEMBL4869136 | 0.83 | TP53 (0.67) | TP53MAPTKDM4EHSD17B10NPC1 | |
| SCHEMBL30896072 | 0.81 | DRD2 (0.47) | TP53MAPTKDM4EHSD17B10POLB | |
| SCHEMBL12060476 | 0.80 | TP53 (0.58) | TP53MAPTKDM4EHSD17B10NPC1 | |
| SCHEMBL25887632 | 0.80 | MAPT (0.48) | TP53MAPTKDM4EHSD17B10POLB | |
| SCHEMBL25308572 | 0.79 | MAPT (0.45) | TP53MAPTKDM4EHSD17B10POLB | |
| SCHEMBL25306362 | 0.79 | MAPT (0.47) | TP53MAPTKDM4EHSD17B10POLB | |
| SCHEMBL31056351 | 0.78 | DRD2 (0.46) | TP53MAPTKDM4EHSD17B10NPC1 | |
| SCHEMBL7381473 | 0.78 | TP53 (0.62) | TP53MAPTKDM4EHSD17B10NPC1 | |
| SCHEMBL3816519 | 0.77 | ALDH1A1 (0.46) | TP53MAPTKDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10646494-B2 | Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-2096923-B1 | HETEROARYL AMIDE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2014-01-22 | — | — | EP | disclosed |
| US-20130172549-A1 | Heteroaryl amide derivatives | H. LUNDBECK A/S (DK) | 2013-07-04 | — | — | US | disclosed |
| US-20130172549-A1 | Heteroaryl amide derivatives | H. LUNDBECK A/S (DK) | 2013-07-04 | — | — | US | disclosed |
| EP-2591675-A1 | Heteroaryl amide derivatives | H. Lundbeck A/S (DK) | 2013-05-15 | — | — | EP | disclosed |
| US-8431593-B2 | Heteroaryl amide derivatives | H. LUNDBECK A/S (DK) | 2013-04-30 | — | — | US | disclosed |
| US-8431593-B2 | Heteroaryl amide derivatives | H. LUNDBECK A/S (DK) | 2013-04-30 | — | — | US | disclosed |
| US-20100216763-A1 | Heteroaryl Amide Derivatives | H. LUNDBECK A/S (DK) | 2010-08-26 | — | — | US | disclosed |
| WO-2009029625-A1 | 4- [HETEROCYCLYL-METHYL] -8-FLUORO-QUINOLIN-2-ONES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009029625-A1 | 4- [HETEROCYCLYL-METHYL] -8-FLUORO-QUINOLIN-2-ONES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| WO-2008066789-A2 | HETEROARYL AMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2008-06-05 | — | — | WO | disclosed |
| US-5525480-A | USED FOR DETERMINATION OF HYDROLASES; COLORIMETRIC ANALYSIS | BOEHRINGER MANNHEIM GMBH (DE) | 1996-06-11 | — | — | US | disclosed |
| US-5457200-A | Oxidative coupling reactions for determination of hydrogen peroxide | BOEHRINGER MANNHEIM (DE) | 1995-10-10 | — | — | US | disclosed |
| US-5334505-A | For colorimetric determination of hydrolases | BOEHRINGER MANNHEIM GMBH (DE) | 1994-08-02 | — | — | US | disclosed |
| US-5234818-A | Detecting hydrogen peroxide, peroxidase by oxidative coupling with electron-rich aromatic compound | BOEHRINGER MANNHEIM GMBH (DE) | 1993-08-10 | — | — | US | disclosed |
| EP-0231244-A1 | 6-ALKYLIDENE PENEMS | BEECHAM GROUP PLC (GB) | 1987-08-12 | — | — | EP | disclosed |
| WO-1987000525-A1 | 6-ALKYLIDENE PENEMS | BEECHAM GROUP P.L.C. (GB) | 1987-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10646494-B2 | Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases | HAVCR2, HCCS, ZC3HAV1 | TP53 700/4885MAPT 4258/4885KDM4E 3735/4885 |
| US-20100216763-A1 | Heteroaryl Amide Derivatives | HCAR2, PIGS, GPR52 | TP53 2708/4885MAPT 4321/4885KDM4E 3851/4885 |
| US-20130172549-A1 | Heteroaryl amide derivatives | HCAR2, PIGS, GPR52 | TP53 2708/4885MAPT 4321/4885KDM4E 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.